Result for
Tag: treatment
September 18, 2020
Corticosteroid Therapy Is Associated with the Delay of SARS-CoV-2 Clearance in COVID-19 Patients
Patients with COVID-19 who received corticosteroids experienced longer time to viral clearance (median 18 days vs 16 days, p<0.001) and hospitalization (median 17 days vs 15 days, p=0.023), in a retrospective multi-center study in China (n=309). Huang et al. (Sept 15, 2020). Corticosteroid Therapy Is Associated with the Delay of SARS-CoV-2 Clearance in COVID-19 Patients….
Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly
A double-blind randomized trial (n=198) of BCG vaccination of elderly patients to protect against subsequent infections (September 2017 through August 2019) found that BCG vaccination increased the time to first infection (median 16 weeks vs 11 weeks) and reduced the incidence of new infections (25% vs 42%). Most of the protection was against respiratory tract…
Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
A propensity score matched cohort study (n=303) found that, compared to patients receiving standard of care, patients receiving colchicine, an anti-inflammatory drug commonly used to prevent or treat gout, had a higher odds of being discharged at 28 days (OR=5.0, 95%CI: 1.25-20.1) and had lower odds of dying at 28 days (OR=0.2, 95% CI: 0.05-0.80)….
September 11, 2020
Effect of Recombinant Human Granulocyte Colony–Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia
• In preliminary findings from a randomized trial at 3 participating centers in China (n=200), recombinant human granulocyte colony-stimulating factor (rhG-CSF) treatment for patients with COVID-19 with lymphopenia but no comorbidities did not accelerate clinical improvement, but the number of patients who developed critical illness (proportion difference=-13%, 95%CI -21.4 to -5.4) or died (HR=0.19, 95%CI…
September 9, 2020
Adverse Outcomes and Mortality in Users of Non-Steroidal Anti-Inflammatory Drugs Who Tested Positive for SARS-CoV-2: A Danish Nationwide Cohort Study
Use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with SARS-CoV-2 infection was not associated with 30-day mortality, hospitalization, ICU admission, mechanical ventilation, or renal replacement therapy in a study of 9,236 SARS-CoV-2-positive Danish residents, of whom 3% filled an NSAID prescription. [EDITORIAL NOTE: A summary of a pre-print version of this manuscript appeared in the…
September 4, 2020
Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: A Systematic Review and Meta-Analysis
A meta-analysis of 12 observational and 3 randomized trials found that the efficacy of chloroquine and hydroxychloroquine was inconsistent across the studies. There was no significant reduction in mortality with hydroxychloroquine use (RR=0.98, 95% CI: 0.66-1.46), and there was a higher risk of ECG abnormalities /arrhythmia associated with hydroxychloroquine/chloroquine use (RR=1.46, 95% CI: 1.04-2.06). Elavarasi…
Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment — United States
• New prescriptions for hydroxychloroquine and chloroquine in the US by medical professionals in specialties that do not routinely use these medications (<2% of prescriptions in 2019) rose from 1,143 in February 2020 to 75,596 in March 2020, an 80-fold increase from March 2019. These medications were reported to have benefits for prevention and treatment…
September 3, 2020
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
NVX-CoV2373, a recombinant nanoparticle vaccine, induced higher levels of anti-spike IgG and neutralizing antibody responses compared to convalescent serum of mostly symptomatic COVID-19 patients. There were no serious adverse events, and events such as fever and sore arm were mild and not long-lasting. These results were from a primary analysis at day 35 of a…
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19
Intravenous dexamethasone plus standard of care compared with standard care alone resulted in 2.3 days (95%CI 0.02-4.4, p=0.04) more ventilator-free days during the first 28 days in a randomized clinical trial among patients with COVID-19 who had moderate to severe respiratory failure (n=299) in Brazil. The trial was stopped early before reaching the planned sample…
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
Administration of hydrocortisone, either as a 7-day fixed-dose course, or dosing only during periods of shock, was associated with being alive and free of ICU-based respiratory or cardiovascular support within 21 days, according to findings of a randomized control trial (n=384) which was stopped early after results were released from another trial. The fixed-dose course…
Previous page Next page